Tags

Type your tag names separated by a space and hit enter

[Metachronous cancers after treatment for undifferentiated nasopharyngeal carcinoma].
Ann Otolaryngol Chir Cervicofac 2004; 121(5):282-5AO

Abstract

OBJECTIVE

To collect second cancers occurring in the head and neck area after treatment by chemotherapy and/or radiotherapy for undifferentiated nasopharyngeal carcinoma in Tunisia.

PATIENTS AND METHODS

This is a retrospective study of patients developing second cancers after treatment for nasopharyngeal UCNT by radiotherapy and/or chemotherapy. To be retained in this study, second tumour had to be histologically different from the initial UCNT, localised in the irradiated area and occurring after a minimal delay of 3 years.

RESULTS

We collect 11 cases of second cancers occurring among 2346 patients treated from 1984 to 2001 in Tunisia (0.46%). Patients have been treated for nasopharyngeal UCNT mainly advanced T3-T4 (72%) or N2-N3 (63%). Median age was 20 years (11 to 48) with a sex-ratio of 0.3 (3 M/8 F). Treatment protocol included primary chemotherapy in 4 cases (adriamycin-cisplatin) or adjuvant (in 4) associated to the loco-regional irradiation at a mean dose of 72 Gy (70 to 75). Median delay of second cancer occurrence was 9 years (3 to 17). Tumors were epidermoid carcinomas in 4 cases, fibrosarcomas (2), osteosarcomas (2), glioblastoma (1) and basocellular carcinomas in 2. Second tumors have been treated by surgery alone in 4 cases and chemotherapy alone in 7 patients. No patient have been reirradiated. Median survival was 17 months, 4 patients died and 7 are still alive including 4 in complete remission (24+, 36, 36 and 48+ months) and 3 with progressing disease (8, 16 and 18 months).

CONCLUSION

Even very rare, second cancers after treatment for UCNT need to be detected and have a poor prognosis.

Authors+Show Affiliations

Institut Salah Azaïz de Tunis, Boulevard du 9 avril, Bab Saadoun, Tunis, Tunisie. hamouda.boussen@rns.tnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

15711481

Citation

Boussen, H, et al. "[Metachronous Cancers After Treatment for Undifferentiated Nasopharyngeal Carcinoma]." Annales D'oto-laryngologie Et De Chirurgie Cervico Faciale : Bulletin De La Societe D'oto-laryngologie Des Hopitaux De Paris, vol. 121, no. 5, 2004, pp. 282-5.
Boussen H, Kochbati L, Oueslati Z, et al. [Metachronous cancers after treatment for undifferentiated nasopharyngeal carcinoma]. Ann Otolaryngol Chir Cervicofac. 2004;121(5):282-5.
Boussen, H., Kochbati, L., Oueslati, Z., Gritli, S., Daoud, J., Gammoudi, A., ... Maalej, M. (2004). [Metachronous cancers after treatment for undifferentiated nasopharyngeal carcinoma]. Annales D'oto-laryngologie Et De Chirurgie Cervico Faciale : Bulletin De La Societe D'oto-laryngologie Des Hopitaux De Paris, 121(5), pp. 282-5.
Boussen H, et al. [Metachronous Cancers After Treatment for Undifferentiated Nasopharyngeal Carcinoma]. Ann Otolaryngol Chir Cervicofac. 2004;121(5):282-5. PubMed PMID: 15711481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Metachronous cancers after treatment for undifferentiated nasopharyngeal carcinoma]. AU - Boussen,H, AU - Kochbati,L, AU - Oueslati,Z, AU - Gritli,S, AU - Daoud,J, AU - Gammoudi,A, AU - Besbes,M, AU - Bouaouina,N, AU - Benna,F, AU - Ladgham,A, AU - Maalej,M, PY - 2005/2/16/pubmed PY - 2005/4/9/medline PY - 2005/2/16/entrez SP - 282 EP - 5 JF - Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris JO - Ann Otolaryngol Chir Cervicofac VL - 121 IS - 5 N2 - OBJECTIVE: To collect second cancers occurring in the head and neck area after treatment by chemotherapy and/or radiotherapy for undifferentiated nasopharyngeal carcinoma in Tunisia. PATIENTS AND METHODS: This is a retrospective study of patients developing second cancers after treatment for nasopharyngeal UCNT by radiotherapy and/or chemotherapy. To be retained in this study, second tumour had to be histologically different from the initial UCNT, localised in the irradiated area and occurring after a minimal delay of 3 years. RESULTS: We collect 11 cases of second cancers occurring among 2346 patients treated from 1984 to 2001 in Tunisia (0.46%). Patients have been treated for nasopharyngeal UCNT mainly advanced T3-T4 (72%) or N2-N3 (63%). Median age was 20 years (11 to 48) with a sex-ratio of 0.3 (3 M/8 F). Treatment protocol included primary chemotherapy in 4 cases (adriamycin-cisplatin) or adjuvant (in 4) associated to the loco-regional irradiation at a mean dose of 72 Gy (70 to 75). Median delay of second cancer occurrence was 9 years (3 to 17). Tumors were epidermoid carcinomas in 4 cases, fibrosarcomas (2), osteosarcomas (2), glioblastoma (1) and basocellular carcinomas in 2. Second tumors have been treated by surgery alone in 4 cases and chemotherapy alone in 7 patients. No patient have been reirradiated. Median survival was 17 months, 4 patients died and 7 are still alive including 4 in complete remission (24+, 36, 36 and 48+ months) and 3 with progressing disease (8, 16 and 18 months). CONCLUSION: Even very rare, second cancers after treatment for UCNT need to be detected and have a poor prognosis. SN - 0003-438X UR - https://www.unboundmedicine.com/medline/citation/15711481/[Metachronous_cancers_after_treatment_for_undifferentiated_nasopharyngeal_carcinoma]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/MDOI-AORL-11-2004-121-5-0003-438X-101019-ART5 DB - PRIME DP - Unbound Medicine ER -